Navigation Links
Low Levels of Brain Chemical May Control Appetite
Date:8/27/2008

Finding could lead to new drugs in fight against obesity, study says

WEDNESDAY, Aug. 27 (HealthDay News) -- A chemical produced in the brain may play a role in regulating appetite and the likelihood of becoming obese, according to a new study.

For the study, researchers looked at a group of 33 people who had WAGR syndrome, a genetic condition that occurs in one in 500,000 to a million people. WAGR is an acronym for the symptoms that accompany the condition: Wilms' tumor (tumor of the kidneys), aniridia (absence of the iris), genital and urinary tract abnormalties, and mental retardation.

Some people with WAGR syndrome lack a gene for the brain chemical, brain-derived neurotrophic factor (BDNF). Animal studies have suggested that BDNF may help control appetite and weight.

The researchers found that 19 (58 percent) of the 33 study participants had deletions of all or a major proportion of one copy of the gene for BDNF and had correspondingly low blood levels of BDNF.

These 19 participants were all obese by age 10 and had a strong tendency to overeat. The participants who had two working copies of the BDNF gene, on the other hand, were no more likely to develop obesity in childhood than the general population and did not report unusually high levels of overeating.

"This is a promising new lead in the search for biological pathways that contribute to obesity," Dr. Duane Alexander, director of the U.S. National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), said in an institute press release. "This finding may eventually lead to the development of new drugs to regulate appetite in people who have not had success with other treatments."

The findings are published in the Aug. 28 issue of the New England Journal of Medicine.

According to senior study author Dr. Jack A. Yanovski, of the NICHD's Unit on Growth and Obesity, BDNF is thought to work in combination with a variety of other substances that regulate appetite and body weight, including the appetite-signaling hormone leptin.

Future research looking into the relationship between BDNF and leptin may lead to the development of new therapies for obesity.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about obesity.



-- Krisha McCoy



SOURCE: U.S. National Institute of Child Health and Human Development, news release, Aug. 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels
2. Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA
3. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
4. Low Iron Levels Cut Cancer Risk in Men With PAD
5. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
6. Moms Vitamin D Levels Affect Babys Dental Health
7. American Lung Association Urges People Living Near Wildfires to Protect Themselves Against Staggering Levels of Unhealthy Air Pollution
8. Research Links Low HDL Levels With Memory Loss
9. UK and US guidelines on kids physical activity levels need rethinking
10. Overcrowding and understaffing in hospitals increases levels of MRSA infections
11. Local Blood Supply at Low Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Guide to ... , No matter on which side of the Atlantic devicemakers do business, ... regulations they have to follow. , In addition to the full text of the ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton School’s ... mid-market executives as a kick-off to the fifth annual CEO Connection Mid-Market Convention. ... the University of Pennsylvania campus, followed by the two-day convention, which will target ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: